GSK - GlaxoSmithKline plc

NYSE - Nasdaq Real Time Price. Currency in USD
41.67
+0.64 (+1.56%)
As of 11:50AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close41.03
Open41.38
Bid41.60 x 1800
Ask41.61 x 800
Day's Range41.18 - 41.62
52 Week Range34.52 - 42.36
Volume1,251,968
Avg. Volume2,457,080
Market Cap99.387B
Beta (3Y Monthly)0.31
PE Ratio (TTM)47.14
EPS (TTM)0.88
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.96 (4.75%)
Ex-Dividend Date2018-11-15
1y Target Est44.30
Trade prices are not sourced from all markets
  • Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
    Zacks2 hours ago

    Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe

    Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.

  • Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC
    Motley Fool5 hours ago

    Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC

    Which stock wins in a matchup between these two big drugmakers?

  • Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
    Zacksyesterday

    Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer

    Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.

  • Business Wire4 days ago

    Once-daily Trelegy Ellipta gains expanded COPD indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.

  • Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
    Zacks5 days ago

    Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ

    Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.

  • Mylan: Why North America Is a Major Market
    Market Realist5 days ago

    Mylan: Why North America Is a Major Market

    In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of GSK.L earnings conference call or presentation 31-Oct-18 2:30pm GMT

    Q3 2018 GlaxoSmithKline PLC Earnings Call

  • GlobeNewswire7 days ago

    Report: Developing Opportunities within Avon Products, Sanofi, Arch Coal, GlaxoSmithKline plc, Chimera Investment, and PTC — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: GlaxoSmithKline and Eli Lilly and Company

    NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...

  • Teva Pharmaceutical’s Performance in the Third Quarter
    Market Realist8 days ago

    Teva Pharmaceutical’s Performance in the Third Quarter

    In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.

  • Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
    Zacks11 days ago

    Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus

    Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.

  • Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View
    Zacks12 days ago

    Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View

    Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.

  • Big pharma leases almost 500,000 square feet for new research center
    American City Business Journals12 days ago

    Big pharma leases almost 500,000 square feet for new research center

    It is one of the largest real estate leases in the Bay Area by traditional drug companies staking out space to establish deeper research and development connections with the region’s hundreds of biotech companies and research universities.

  • GlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript
    Motley Fool13 days ago

    GlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript

    GSK earnings call for the period ending September 30, 2018.

  • Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?
    Zacks13 days ago

    Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?

    Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.

  • Associated Press13 days ago

    Glaxo: 3Q Earnings Snapshot

    On a per-share basis, the Brentford Middlesex, Britain-based company said it had profit of 66 cents. Earnings, adjusted for one-time gains and costs, came to 83 cents per share. The results fell short ...

  • Reuters13 days ago

    GSK feels shingles vaccine boost, but shares slip on drugs mix

    GlaxoSmithKline's third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focussed on some drugs missing forecasts. GSK beat market a company-compiled analyst forecast with a 14 percent rise in adjusted earnings per share to 35.5 pence, on sales of 8.09 billion pounds ($10 billion), which were up 6 percent on a constant exchange rate basis. Chief Executive Emma Walmsley, who is trying to reinvigorate GSK's pharmaceutical business, its largest division which has lagged rivals in producing new blockbuster drugs, said stronger commercial execution, new launches, notably shingles vaccine Shingrix, and better cost control was driving GSK's growth.

  • Reuters13 days ago

    GSK feels shingles vaccine boost, but shares slip on drugs mix

    GlaxoSmithKline's third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focussed on some drugs missing forecasts. GSK declared a 19 pence dividend for the quarter, and said it continued to expect 80 pence for the full year.

  • The Wall Street Journal13 days ago

    [$$] Glaxo's Shingles Vaccine Gave Earnings a Shot in the Arm

    PLC reported a rise in third-quarter earnings and said full-year profit would come in at the top end of expectations, mainly thanks to strong demand for its new shingles vaccine. Demand for Shingrix, which is aimed at people age 50 and over, has outpaced Glaxo’s expectations since it launched the vaccine late last year. The CDC also recommended that adults who had previously received Zostavax should still receive Shingrix.

  • GSK feels shingles vaccine boost, but shares slip on drugs mix
    Reuters13 days ago

    GSK feels shingles vaccine boost, but shares slip on drugs mix

    GlaxoSmithKline's (GSK.L) third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focussed on some drugs missing forecasts. GSK beat market a company-compiled analyst forecast with a 14 percent rise in adjusted earnings per share to 35.5 pence, on sales of 8.09 billion pounds ($10 billion), which were up 6 percent on a constant exchange rate basis. Chief Executive Emma Walmsley, who is trying to reinvigorate GSK's pharmaceutical business, its largest division which has lagged rivals in producing new blockbuster drugs, said stronger commercial execution, new launches, notably shingles vaccine Shingrix, and better cost control was driving GSK's growth.

  • Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line
    Zacks13 days ago

    Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line

    Glaxo beat earnings estimates while sales were in-line in the third quarter of 2018.

  • Financial Times13 days ago

    [$$] GSK’s shingles vaccine helps it shrug off Advair fears

    The UK drugmaker said it was “tightening full-year guidance range towards the upper end of previous expectations” and now expected full-year adjusted earnings per share to grow 8-10 per cent in constant currencies. Emma Walmsley, chief executive, said GSK was “confident of meeting this even if there is an introduction of a generic competitor to Advair in the US before year end”. The company had previously said it expected adjusted earnings per share growth of 7-10 per cent for 2018 but warned that if a generic competitor was launched, this would fall to between 4 and 7 per cent.

  • The Wall Street Journal13 days ago

    [$$] GlaxoSmithKline 3Q Profit Rose, Raises Guidance

    PLC (GSK.LN) said Wednesday that third-quarter net profit rose 17% and revised its full-year outlook toward the upper end of its forecasted range on the back of a strong performance of its shingles vaccine. Adjusted operating profit, a measure which strips out one-time items, was GBP2.52 billion--a 6% increase at constant exchange rates when compared with the third quarter of 2017. The FTSE 100-listed drugmaker narrowed its outlook, and said it sees adjusted earnings per share increasing between 8% to 10% at constant exchange rates for the full-year regardless of whether a generic Advair competitor is launched.

  • Reuters14 days ago

    Long-lasting HIV injection is a step closer after second GSK study

    A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators. The experimental two-drug injection of cabotegravir and rilpivirine was shown to suppress the HIV virus in a cohort of adults who had not been on a long-established daily three-drug oral regimen, GSK's majority-owned HIV unit ViiV Healthcare said. In the study, adults with HIV were first put on a 20-week three-drug programme of daily tablets to suppress the virus before being switched to monthly injections.

  • Sanofi’s Q3 Estimates: Expect Revenue Growth
    Market Realist14 days ago

    Sanofi’s Q3 Estimates: Expect Revenue Growth

    As we discussed earlier, analysts expect Sanofi’s (SNY) revenues to grow 3.3% to 9.3 billion euros during the third quarter. In this part, we’ll discuss Sanofi’s business structure and the estimates for each segment during the third quarter.